About NanGenex Inc.
NanGenex is a Budapest based biotech company and was established in 2006 to develop the continuous flow based NanoActive™ HT Drugability Enabling Technology platform and the related full scale (scale-down and scale-up), intelligent and integrated, GMP compliant instrument line.
Today, NanGenex has 10 out of the 20 largest pharma companies and 3 out of the 5 leading agrochemical companies among its partners.
In 2010, the Company has founded NanoForm Therapeutics in London, UK for the commercialization of 11 proprietary life cycle extension NanoActive™ drugs developed from current blockbusters.
NanGenex is member of the DRGT Group. Headquartered in Dublin, Ireland, Druggability Technologies, through its subsidiaries, is developing and commercializing its proprietary NanoActive™ high throughput technology platform. This platform delivers improvements in compound solubility, permeability and pharmacokinetics that can be applied across a diverse universe of chemical and biological compounds. DRGT’s experience in improving the bioavailability and kinetic profile of drugs is born of a heritage of three decades of scientific and industrial knowledge gained through successful commercial ventures in bio- and chemo-informatics, combinatorial chemistry, chemical genomics, flow chemistry, colloidal chemistry, and nanotechnology.